| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 12/02/2004 | US20040242646 Dantrolene as anesthetics for pumping injection |
| 12/02/2004 | US20040242640 Dual-release compositions of a cyclooxygenase-2 inhibitor |
| 12/02/2004 | US20040242632 Method for treating inflammatory bowel disease |
| 12/02/2004 | US20040242626 Nasal delivery of apomorphine |
| 12/02/2004 | US20040242625 Nasal delivery of apomorphine |
| 12/02/2004 | US20040242624 Nasal delivery of apomorphine |
| 12/02/2004 | US20040242555 high dosage regimen delivered from a modified release formulation such as multilayer tablets |
| 12/02/2004 | US20040242546 Compositions and method for treating infection in cattle and swine |
| 12/02/2004 | US20040242545 Remedy for glaucoma comprising as the active ingredient compound having p13 kinase inhibitory effect |
| 12/02/2004 | US20040242544 Stabilized derivatives of ascorbic acid-3-phosphate |
| 12/02/2004 | US20040242538 Method to improve complexation efficacy and produce high-energy cylodextrincomplexes |
| 12/02/2004 | US20040242536 controlled-release mixtures of plant extracts, gelation polymers and drugs such as ximelagatran, used for prophylaxis of cardiovascular disorders |
| 12/02/2004 | US20040242534 Lyophilized powder of lentinan and the process of preparation thereof |
| 12/02/2004 | US20040242527 System and method for enhancing cardiac signal sensing by cardiac pacemakers through genetic treatment |
| 12/02/2004 | US20040242507 Topical formulations of a lipophilic anthracycline with a second active ingredient and carrier; antiproliferative agents for skin and mucus membrane disorders; side effect reduction in psoriasis treatment with valrubicin |
| 12/02/2004 | US20040242506 Formed from paroxetine hydrochloride and ammonium glycyrrhyzinate by precipitation, spray, vacuum or freeze drying, or evaporation to glass; solid or oil; masks the bitter taste of paroxetine and has a distinctive licorice flavor; antidepressants; Parkinson's disease |
| 12/02/2004 | US20040242497 Ammonium glycyrrhyzinate masks the bitter taste of paroxetine hydrochloride and has a distinctive licorice flavor; dispersable powders or tablets; antidepressants; Parkinson's disease |
| 12/02/2004 | US20040242489 Method for improving stability of a bone-connecting implant |
| 12/02/2004 | US20040242478 5-cnac as oral delivery agent for parathyroid hormone fragments |
| 12/02/2004 | US20040242460 Using fatty acid, storage stable |
| 12/02/2004 | US20040242416 Compositions and methods for intracellular delivery |
| 12/02/2004 | US20040241855 Polyoxyethylene glycol (peg)-lipid-immunogen conjugates; for incorporation into liposomes to enhance intracelllar delivery of nucleic acids and drugs |
| 12/02/2004 | US20040241772 Solid composition cantaining bacillus-type non-pathogenic bacterial spores |
| 12/02/2004 | US20040241424 An article comprising a substrate having an identifiable code pattern of fluorescent water soluble quantum dots of different colors operably bound to the substrate and have identifiable code pattern including encoded data |
| 12/02/2004 | US20040241248 Crosslinking the carboxylic acid groups in a glycosaiminoglycan with a primary amine in a lipid to form particles that can be used to encapsulate various drugs, especially chemotherapeutic agents |
| 12/02/2004 | US20040241247 Foaming a fluid mixture of a polymer and a liquid diluent with a gas and contacting with foam produced with solid particles of an average size of less than 2500 micrometers; either the fluid or the particles contain a drug; may be pressed to form a tablet |
| 12/02/2004 | US20040241245 Compositions and methods for treatment of premature ejaculation |
| 12/02/2004 | US20040241244 Neuronal growth enhancement by prostaglandin compositions and methods |
| 12/02/2004 | US20040241243 Angiogenesis promotion by prostaglandin compositions and methods |
| 12/02/2004 | US20040241242 Thin film delivery systems for volatile decongestants |
| 12/02/2004 | US20040241240 A copolymer of N-vinyl-2-pyrrolidone with e.g., ethylhexyl acrylate and 1,6-hexanediol diacrylate, enhances absorption of a hardly soluble drug such as one having an ergoline skeleton, e.g., a pergolide or a bromocriptine; improved skin permeability |
| 12/02/2004 | US20040241239 Mixed complexes for masking the taste of bitter active substances |
| 12/02/2004 | US20040241238 Hydrolyzing and foaming a mixture of metal oxides (particularly tetraethyl silicate and triethoxy phsophate) in the presence of an acid catalyst and surfactants and molding, aging, drying and thermally stabilizing the product; used for bone implants or grafts, tissue engineering substrates and filters |
| 12/02/2004 | US20040241236 shell provides a delay of greater than one hour for the onset of dissolution of the active ingredient upon contacting of the dosage form with a liquid medium such as water or gastrointestinal fluids, and the delay is independent of the pH |
| 12/02/2004 | US20040241235 Core of drug and binder having at least three successive coating layers starting from the core: a delayed or sustained release polymeric coating; a hydrophobic coating containing a waxy compound; and another polymeric coating having a complementary release function and conditioning the suspension medium |
| 12/02/2004 | US20040241234 Core of a water-soluble active agent (particularly a salt of methylphenidate, fluoxetine, or oxybutynin) and a waxy material coated the active agent and a hydrophilic polymer, especially a cellulose polymer |
| 12/02/2004 | US20040241233 Sustained release heterodisperse hydrogel systems- amorphous drugs |
| 12/02/2004 | US20040241232 Comprising inhalable medicament particles having a mass median aerodynamic diameter no greater than 10 mu m and 50% of a non-respirable excipient fraction comprising low density excipient particles having an aerodynamic diameter greater than 10 mu m and a geometric diameter greater than 30 mu m |
| 12/02/2004 | US20040241231 Carrier matrix containing a plurality of particles having open pores or capillary spaces which serve as active substance reservoirs and contain at least one active substance; small thickness |
| 12/02/2004 | US20040241230 Modulated release from biocompatible polymers |
| 12/02/2004 | US20040241229 Sustained-release composition and process for producing the same |
| 12/02/2004 | US20040241227 1900 to 2600 mg amoxycillin and an amount of potassium clavulanate such that the weight ratio of amoxycillin to clavulanate is 2:1 to 20:1, at a dosage regiment/interval of about 12 hours; pharmacokinetics; time release |
| 12/02/2004 | US20040241226 Administering a tyrosine kinase inhibitor, more particularly a non toxic, potent and selective c-kit inhibitor, wherein said inhibitor is unable to promote death of IL-3 dependent cells cultured to presence of IL-3 |
| 12/02/2004 | US20040241223 Oral dosage forms for macromolecular drugs |
| 12/02/2004 | US20040241222 Lipid-polymer-conjugates compositions |
| 12/02/2004 | US20040241221 Application method for enhanced oral assimilation through oral and gastrointestinal membranes, of liquids containing insulin, or other drugs, by enclosing them in stable, nanometer size, vesicles formed with a special combination of essential phospholipids (EPL) to minimize side effects and maximize absorption in oral applications |
| 12/02/2004 | US20040241219 System comprising back layer, protective layer and at least one active-compound-containing polymer matrix comprising a polyacrylate which contains extremely reduced number of functional groups; in one embodiment polyacrylate is free of hydroxyl and/or carboxyl groups |
| 12/02/2004 | US20040241218 Transdermal patch, wherein dosage form includes at least one activating agent and at least one inactivating agent where inactivating agent is released only when dosage form is solubilized, opened, chewed and/or cut apart, but it is not transdermally delivered to patient |
| 12/02/2004 | US20040241217 Method for administration of immune modulators in systemic and localized immune disorders |
| 12/02/2004 | US20040241209 Comprising at least one active ingredient selected from fat-soluble vitamins, water soluble vitamins, amino acids, trace inorganic compounds, organic acids, sucrose and starch syrup, sodium bicarbonate, and carbon dioxide, with the proviso that at least one vitamin is included; for children |
| 12/02/2004 | US20040241208 Comprising an active ingredient and a carbohydrate, at least a portion of which carbohydrate is crystallized and has an average particle size of 2 to 35 microns, composition having a moisture content of 10 to 13 percent; soft tablet |
| 12/02/2004 | US20040241207 Comprising a contact lens having dispersed therein as nanoparticles having a particle size less than 50 nm, an ophthalmic drug nanoencapsulated in a material from which ophthalmic drug is capable of diffusion into and migration through contact lens |
| 12/02/2004 | US20040241206 Use of nanoparticles as carriers for biocides in ophthalmic compositions |
| 12/02/2004 | US20040241204 Sustained release pharmaceutical composition |
| 12/02/2004 | US20040241203 Porous matrix comprising cross-linked particles |
| 12/02/2004 | US20040241202 Core coated with alternating polyelectrolyte layers of opposite charges having a biologically active molecule(s)of a molecular weight less <10,000 Da. fixed or included to a layer(s); nanoarchitecture; dryable; storage stability; complex cell modulation systems; extracellular matrix network, e.g., patch |
| 12/02/2004 | US20040241184 Fermentation product of cyptoporous volvatus and its preparation method and use |
| 12/02/2004 | US20040241179 Compositions and methods using lactadherin or variants thereof |
| 12/02/2004 | US20040241155 Dilution resistant viscoelastic compositions |
| 12/02/2004 | US20040241134 Colon cleansing compositions and methods of use therefor |
| 12/02/2004 | US20040241104 Aerosol device comprising a cosmetic composition comprising at least one polyurethane and at least one propellant comprising dimethyl ether and at least one C3-C5 hydrocarbon |
| 12/02/2004 | US20040241103 Propellant particles of first drug suspended in propellant; second drug dissolved in aerosol forms |
| 12/02/2004 | US20040241101 Stabilized aerosol dispersions |
| 12/02/2004 | US20040241100 Nasally administrable compositions of zolpidem and methods of use |
| 12/02/2004 | US20040241099 Foamable pharmaceutical compositions and methods for treating a disorder |
| 12/02/2004 | US20040241094 Oily paclitaxel composition and formulation for chemoembolization and preparation method thereof |
| 12/02/2004 | US20040238769 Radiofrequency-controlled device for release/sampling of substances |
| 12/02/2004 | DE202004009180U1 Formulation comprising glycine-containing gel, useful, by external or internal application, for treatment or prevention of e.g. allergy, sunburn and stress |
| 12/02/2004 | DE19922193B4 Wasserlösliches Konzentrat, bestehend aus ätherischen Ölen mikroverkapselt in einem Liposomensystem, ein Verfahren zu seiner Herstellung und die Verwendung Water-soluble concentrate consisting of essential oils in a microencapsulated liposome system, a process for its preparation and the use |
| 12/02/2004 | DE10322293A1 Post-wetting agent contains substances for supplying cornea of human eye |
| 12/02/2004 | DE10321029A1 Arzneimittel mit Selenit Drugs with selenite |
| 12/02/2004 | DE102004005783A1 Stable depot system for prolonged release of protein or peptide drugs, e.g. insulin, comprising phosphatidyl choline, cholesterol and cationic lipids |
| 12/02/2004 | CA2526454A1 Gel-assisted production of small particles |
| 12/02/2004 | CA2526289A1 Combination chemotherapy comprising 5-fluorouracil or a derivative thereof and a liposomal platinum complex |
| 12/02/2004 | CA2526278A1 Combination chemotherapy comprising a liposomal platinum complex |
| 12/02/2004 | CA2525943A1 Salmeterol and ciclesonide combination |
| 12/02/2004 | CA2525804A1 Use of chondroitinase abc enzyme for the treatment of cns injuries |
| 12/02/2004 | CA2525789A1 Compositions containing a combination of a pharmaceutical agent or a cosmetic agent and an oxy group-bearing aromatic aldehyde |
| 12/02/2004 | CA2525756A1 Carrier particles |
| 12/02/2004 | CA2525744A1 Improved metered dose inhaler |
| 12/02/2004 | CA2524818A1 Protein kinase c peptides for use in withdrawal |
| 12/02/2004 | CA2524538A1 Solid particles comprising an anticonvulsant or an immunosuppressive coated with one or more surface modifiers |
| 12/02/2004 | CA2523787A1 Dissolvable backing layer for use with a transmucosal delivery device |
| 12/02/2004 | CA2521575A1 Antibiotic composition |
| 12/02/2004 | CA2521558A1 Novel composition for hormonal balance and uses thereof |
| 12/02/2004 | CA2489124A1 Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof |
| 12/01/2004 | EP1481705A1 A radiofrequency-controlled device for release / sampling of substances |
| 12/01/2004 | EP1481695A1 Formulations of hyaluronic acid for delivery of osteogenic proteins |
| 12/01/2004 | EP1481666A1 A composition for re-establishment of the vaginal ecosystem |
| 12/01/2004 | EP1481665A1 Novel lipid mixtures for synthetic surfactants |
| 12/01/2004 | EP1481597A1 Hard coating method |
| 12/01/2004 | EP1481596A1 Use of microcapsules |
| 12/01/2004 | EP1481211A1 Process for co-spray drying liquid herbal extracts with dry silicified mcc |
| 12/01/2004 | EP1481017A1 Biodegradable polymeric material for biomedical applications |
| 12/01/2004 | EP1480996A1 Amorphous fluticasone 2-furoate, pharmaceutical compositions thereof and its conversion to the crystalline unsolvated form |
| 12/01/2004 | EP1480990A1 Compounds for use as surfactants |
| 12/01/2004 | EP1480985A1 Salt of benzosulfonic acid containing clopidogrel and use thereof for the production of pharmaceutical formulations |
| 12/01/2004 | EP1480736A2 Microcapsules having high carotenoid content |
| 12/01/2004 | EP1480711A1 Flow condition sensor for infusion device |
| 12/01/2004 | EP1480691A2 Agglomerated particles for aerosol drug delivery |